Tiziana Life Sciences Chairman Gabriele Cerrone Buys 25K Shares At $1.60; Now Holds 36.28% Of Issued Capital
Author: Benzinga Newsdesk | September 05, 2025 08:35am
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 25,000 common shares at $1.60 per share, bringing his total holding to 43,277,143 common shares, which is 36.28% of issued share capital.
Posted In: TLSA